All In Biotech

Drug Trial Radar · NCT04396821

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination With Nivolumab or Standard of Care in Patients With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

May 28, 2020

Primary completion

Jun 30, 2027

Study completion Sep 30, 2027

Sponsor

Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
May 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic cancers.

Conditions

  • Advanced Cancer
  • Gastric Cancer
  • Gastroesophageal-junction Cancer
  • Pancreatic Cancer

Interventions

  • TST001Drug

    TST001 is a humanized IgG1 monoclonal antibody.

  • Nivolumab Injection [Opdivo]Drug

    Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies

  • mFOLFOX6Drug

    mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.

  • GemcitabineDrug

    Chemotherapy medication

  • Albumin-Bound PaclitaxelDrug

    Chemotherapy medication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participant Safety as characterized by frequency and severity of adverse eventsTime frame: up to 100 days following last dose
  2. Maximum Tolerated Dose (MTD or Recommended Phase 2 Dose (RP2D)Time frame: up to 100 days following last dose
  3. Participant Safety and Tolerability of TST001 in combination with Nivolumab as characterized by frequency and severity of adverse eventsTime frame: Up to 100 days following last dose
  4. Participant Safety and Tolerability of TST001 in combination with Nivolumab and mFOLFOX6 as characterized by frequency and severity of adverse eventsTime frame: Up to 100 days following last dose
  5. Participant Safety and Tolerability of TST001 in combination with gemcitabine and albumin-bound paclitaxel as characterized by frequency and severity of adverse eventsTime frame: Up to 100 days following last dose

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson

    Gilbert, Arizona

  • University of Arizona

    Tucson, Arizona

  • Yale University

    New Haven, Connecticut

  • Florida Cancer Specialists

    Sarasota, Florida

  • Emory University

    Atlanta, Georgia

  • University of Kansas, School of Medicine

    Kansas City, Kansas

  • Washington University

    St Louis, Missouri

  • Memorial Sloan Kettering

    New York, New York

  • Stony Brook Cancer Center

    Stony Brook, New York

  • Wake Forest Baptist Comprehensive Cancer Center

    Winston-Salem, North Carolina

  • Gabrail Cancer Research

    Canton, Ohio

  • Pennsylvania Cancer Specialist Research Institute

    Gettysburg, Pennsylvania

  • Allegheny Hospital

    Pittsburgh, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Vanderbilt University

    Nashville, Tennessee

  • NEXT Oncology

    Austin, Texas

  • Swedish Cancer Institute

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.